European Journal of Nuclear Medicine and Molecular Imaging

Title Publication Date Language Citations
FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC2018/04/11English293
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study2011/09/03English292
The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials2008/08/15English290
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors2014/10/02English286
Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA2017/05/25English285
Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer2010/11/06English285
A gradient-based method for segmenting FDG-PET images: methodology and validation2007/03/13English283
The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer2007/09/22English282
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors2008/04/22English279
Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE2010/07/02English278
Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis2011/08/19English271
Radioimmunotherapy with alpha-emitting nuclides1998/09/01269
Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy2014/02/28English264
Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer2016/06/12English263
213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience2014/07/29English262
PET attenuation coefficients from CT images: experimental evaluation of the transformation of CT into PET 511-keV attenuation coefficients2002/04/19English260
Yttrium-90 DOTATOC: first clinical results1999/10/27258
The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease2005/03/04English254
Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience2013/12/19English252
Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate2003/01/09English251
Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?2007/01/16English250
18F-FDG brain PET hypometabolism in patients with long COVID2021/01/26English248
Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology2010/06/25English245
Current use and future potential of organometallic radiopharmaceuticals2002/11/01245
In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM2003/04/12English244
[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients2006/07/25English243
EANM guidelines for ventilation/perfusion scintigraphy2009/06/27English242
Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours1997/12/17240
O -(2-[ 18 F]Fluoroethyl)- l -tyrosine and l -[methyl- 11 C]methionine uptake in brain tumours: initial results of a comparative study2000/04/28239
Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma2010/05/27English238